{
  "abstract": "Liver resection remains the main curative option for many patients with primary and secondary liver malignancies, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma and colorectal liver metastases. However, a substantial proportion of patients are not eligible for surgery due to insufficient future liver remnant (FLR) for sustained postoperative liver function. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) was developed just over a decade ago to address this specific problem and to overcome the limitations of traditional hypertrophy-induced strategies, such as perioperative portal vein embolisation and ‘classic’ two-stage hepatectomy. By combining right portal vein ligation with in situ parenchymal transection, ALPPS induces a remarkably rapid increase in FLR volume, enabling patients within advanced liver malignancies and marginal FLR to undergo potentially curative resection within just a few days.1 The initial multicentre ALPPS registry analysis reported higher perioperative morbidity and mortality in elderly patients, but confirmed improved resectability.2 For liver surgeons and oncologists, ALPPS represents a challenging clinical trade-off: it can offer a surgical opportunity for patients who would otherwise be inoperable, yet it does so with a narrow safety margin. Given the persistent debate over the biological basis and safety profile of ALPPS, mechanistic studies are essential for understanding why the procedure succeeds in some patients yet fails in others.",
  "authors": [
    {
      "affiliations": [
        "Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA"
      ],
      "name": "Yankai Wen"
    },
    {
      "affiliations": [
        "Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA"
      ],
      "name": "Cynthia Ju"
    }
  ],
  "title": "CD177+ neutrophils: new drivers of liver regeneration",
  "uid": "dd88dce9-48af-5ebe-8bca-98affdddda5c"
}